Spontaneous intracerebral hemorrhage represents a devastating subtype of acute stroke associated with severe neurological morbidity and elevated mortality. Acute parenchymal extravasation often triggers secondary neuroinflammatory cascades, cortical irritation, and metabolic crises. Consequently, clinicians frequently encounter post-stroke seizures during acute neurocritical care. The clinical decision regarding seizure prophylaxis in SICH remains highly debated across neurocritical care units worldwide. Historical observational data suggested that seizure activity exacerbates secondary brain injury by elevating intracranial pressure, worsening cerebral metabolic demand, and promoting hematoma expansion. However, routine primary prophylaxis with anti-seizure medications has generated conflicting recommendations among international stroke guidelines. While classical guidelines often advise against routine prophylaxis in unselected patients, neurointensivists continue to prescribe these agents selectively in routine bedside practice. A landmark comprehensive systematic review and meta-analysis led by Ning and colleagues provides crucial clarity on this long-standing dilemma. By evaluating 22 studies encompassing 8,288 adult patients, the investigation analyzes the true efficacy of preventative anti-seizure therapies on early seizures, long-term epileptogenesis, mortality, and disability. Furthermore, this study clarifies the key clinical determinants driving clinician prescribing patterns in real-world acute neurovascular settings.

Mechanistic Rationale and Early Seizure Prophylaxis in SICH

Acute intracerebral bleeding exposes cortical gray matter to toxic blood breakdown products, thrombin, and free radical cascades. This localized irritation rapidly destabilizes neuronal membranes, provoking acute focal or generalized epileptic discharges. When early seizures occur within the initial seven days, they substantially elevate cerebral metabolic demand, increase intracranial pressure, and aggravate perihematomal edema. Therefore, suppressing early hyperexcitability remains a vital priority during acute stabilization. The meta-analysis by Ning and co-investigators demonstrated that prophylactic anti-seizure medications significantly reduced the odds of early seizures by sixty-one percent compared to non-prophylactic management. Specifically, the pooled odds ratio stood at 0.39 with a 95% confidence interval between 0.20 and 0.76, demonstrating high statistical significance and zero heterogeneity. This robust risk reduction highlights that immediate pharmacological stabilization successfully dampens the transient neurochemical storm occurring in acute parenchymal injury. Consequently, preventing acute paroxysmal events shields vulnerable penumbral tissues from hypermetabolic exhaustion and secondary hypoxic stress during the critical first week. However, clinicians must carefully differentiate acute electrical stabilization from permanent disease modification, ensuring that early therapeutic intervention directly aligns with the underlying pathophysiological timeline of acute hematoma evolution.

Impact of Seizure Prophylaxis on Late Seizures and Epileptogenesis

Although early seizure prevention demonstrates notable acute success, whether prophylactic anti-seizure therapy mitigates chronic epileptogenesis remains a distinct clinical question. Late unprovoked seizures, occurring after the initial seven days, stem primarily from chronic gliosis, hemosiderin deposition, persistent microvascular dysfunction, and aberrant structural neural circuit remodeling. The systematic review evaluated long-term outcomes to assess whether transient prophylactic pharmacotherapy prevents delayed epilepsy. Interestingly, the pooled data revealed no statistically significant reduction in late seizures among patients receiving primary prophylaxis, demonstrating an odds ratio of 1.09 with a confidence interval between 0.74 and 1.59. This crucial finding reinforces the biological principle that acute antiepileptic therapy merely elevates the seizure threshold temporarily rather than modifying structural epileptogenic tissue remodeling. Furthermore, the analysis showed no demonstrable improvement in long-term functional recovery, defined as a modified Rankin Scale score below three, nor did it alter overall mortality rates. Thus, while prophylactic medications provide transient protection against acute symptomatic seizures, they do not modify the chronic neuropathological trajectory or halt post-stroke epileptogenesis. Clinicians should therefore recognize that preventative regimens do not confer sustained neuroprotection against chronic unprovoked seizure development.

Clinical Determinants Influencing Antiseizure Prescribing Patterns

Understanding which specific patient subgroups benefit most from preventative therapy requires an examination of real-world clinical determinants. The meta-analysis uncovered distinct prescribing behaviors among neurointensivists and stroke physicians when deciding on seizure prophylaxis in SICH. Clinicians demonstrated a nearly threefold higher propensity to prescribe prophylactic anti-seizure medications to patients presenting with lobar intracerebral hemorrhage, yielding an odds ratio of 2.78 with a confidence interval of 2.06 to 3.73. This clinical preference aligns with established neuroanatomical principles, as hematomas directly involving the cerebral cortex disrupt cortical circuits far more severely than deep subcortical or basal ganglia hemorrhages. Additionally, factors such as larger baseline hematoma volumes, significant mass effect, concurrent intraventricular extension, and younger patient age frequently influenced proactive antiepileptic initiation. However, substantial practice variability persists globally due to divergent departmental protocols and heterogeneous interpretation of previous guideline recommendations. By identifying these dominant clinical determinants, the study underscores how bedside practitioners intuitively risk-stratify patients according to anatomical cortical involvement, even while awaiting formal personalized treatment algorithms from randomized clinical trials.

Balancing Drug Toxicities and Pharmacotherapy Selection

The choice of specific anti-seizure agents in acute neurocritical care requires careful consideration of drug safety profiles, metabolic pathways, and systemic toxicities. Historically, older first-generation anticonvulsants such as phenytoin and fosphenytoin were widely utilized for acute seizure prevention. Nevertheless, accumulating literature and guideline reviews associate classical sodium channel blockers with undesirable cognitive blunting, cutaneous hypersensitivity, hepatic cytochrome induction, and poor functional recovery in acute stroke cohorts. In contemporary neurovascular practice, non-hepatic second-generation agents such as levetiracetam have largely supplanted older medications due to their favorable pharmacokinetics, minimal drug interactions, and convenient parenteral formulations. Levetiracetam allows rapid therapeutic dosing without requiring intricate serum level monitoring or causing hepatic enzyme interference. However, clinicians must remain vigilant regarding potential neuropsychiatric adverse reactions, including behavioral agitation, somnolence, and mood alterations, particularly in intensive care environments. Furthermore, emerging evidence suggests that valproate and brivaracetam may offer alternative neuroprotective and anti-epileptogenic profiles, though rigorous comparative head-to-head randomized trials remain necessary. Ultimately, when physicians opt for prophylaxis, selecting an agent with minimal neurocognitive toxicity is essential to avoid compounding acute neurological deficits.

Translating Meta-Analytic Findings into Bedside Practice

Translating these pooled meta-analytic findings into daily neurovascular care requires a nuanced, individualized clinical strategy. Routine universal prophylaxis for every acute hemorrhage patient appears neither necessary nor supported by long-term functional outcome data. Instead, clinicians should reserve short-term prophylactic anti-seizure medications for carefully selected high-risk cohorts, particularly individuals with superficial lobar hemorrhages, extensive cortical disruption, or surgical hematoma evacuation. When initiated, modern clinical consensus and decision-analytic models recommend limiting prophylactic treatment to a short duration of five to seven days post-ictus in the absence of documented seizures. Prolonged indefinite treatment exposes patients to unnecessary polypharmacy and adverse drug reactions without delivering demonstrable long-term benefits. Additionally, continuous or serial electroencephalography monitoring plays a pivotal diagnostic role in identifying non-convulsive status epilepticus in comatose or deteriorating patients. If clinical or electrographic seizures emerge, clinicians must immediately transition the patient from short-term prophylaxis to formal secondary antiepileptic management. By adopting this balanced, risk-stratified paradigm, healthcare teams can successfully prevent destabilizing early seizures while safeguarding long-term cognitive and functional rehabilitation.

Does seizure prophylaxis improve overall functional recovery after spontaneous intracerebral hemorrhage?

Current systematic evidence shows that prophylactic anti-seizure medications do not improve long-term functional recovery or reduce overall mortality. Although prophylaxis effectively prevents early clinical seizures during the first week, it does not alter underlying tissue damage, chronic neurodisability, or long-term modified Rankin Scale scores in stroke survivors.

Which patients with spontaneous intracerebral hemorrhage are most suitable for prophylactic anti-seizure medications?

Prophylactic therapy is most commonly considered for patients at elevated risk for cortical irritation, particularly those with lobar hemorrhage, extensive cortical involvement, larger hematoma volume, or neurosurgical hematoma evacuation. Deep subcortical hemorrhages rarely require primary prophylaxis unless clinical or electrographic epileptiform activity develops during acute hospital admission.

What is the recommended duration for prophylactic anti-seizure therapy when initiated?

When clinicians initiate primary seizure prophylaxis in high-risk intracerebral hemorrhage cases, guidelines and expert consensus recommend limiting therapy to a short course of five to seven days. Discontinuing the medication within this early window avoids unnecessary chronic polypharmacy, adverse behavioral effects, and drug toxicity without increasing delayed seizure risk.

Disclaimer: This content is for informational and educational purposes only and does not constitute formal medical advice, diagnosis, or treatment. Healthcare providers must exercise independent clinical judgment and correlate findings with clinical presentations. Refer to the latest local and national guidelines for clinical practice.

References

1. Ning X et al. Prophylactic use of antiepileptics in spontaneous intracerebral hemorrhage: a systematic review and meta-analysis focusing on early seizures and clinical determinants. Neurosurg Rev. 2026 Aug 22. doi: 10.1007/s10143-026-04461-0. PMID: 42631764.


2. Greenberg SM, Ziai WC, Cordonnier C, et al. 2022 Guideline for the Management of Patients With Spontaneous Intracerebral Hemorrhage: A Guideline From the American Heart Association/American Stroke Association. Stroke. 2022;53(7):e282-e361.


3. Claassen J, Vespa PM, et al. Guidelines for Seizure Prophylaxis in Patients Hospitalized with Nontraumatic Intracerebral Hemorrhage: A Clinical Practice Guideline for Health Care Professionals from the Neurocritical Care Society. Neurocrit Care. 2025;42(1):1-18.